Javascript must be enabled to continue!
Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists
View through CrossRef
ABSTRACT
Analogues of LHRH can be used for the treatment of sex hormone-dependent tumours. The nude mouse is a valuable model for the investigation of transplanted human cancers, but there is a body of literature reporting that the function of the pituitary-gonadal axis in normal (immunocompetent) and nude (immunocompromized) mice, unlike that of other species, cannot be suppressed by the administration of LHRH agonists and antagonists. To explore this view further, long-term experiments were carried out in nude male mice, in which sustained-release formulations of the agonist [d-Trp6]-LHRH and of two new potent antagonists were used which permitted a continuous release of the peptides into the circulation. Nude male mice were treated for 28-30 days with 50 μg of antagonists [Ac-d-Nal(2)1,d-Phe(4Cl)2,d-Trp3,d-Cit6,d-Ala10]-LHRH (SB-30) or [Ac-d-Nal(2)1,d-Phe(4Cl)2,d-Pal(3)3,d-Cit6,d-Ala10]-LHRH (SB-75)/day delivered by osmotic minipumps. Some mice were injected twice a day with 25 μg SB-75. Other groups received microcapsule preparations of the agonist [d-Trp6]-LHRH, releasing 25 or 12·5 μg/day for 30 days. At autopsy, in mice which received 50 μg SB-30 or SB-75/day by minipumps, there was a significant decrease in weights of testes, ventral prostate and seminal vesicles compared with controls. [d-Trp6]-LHRH microcapsules at either dose also reduced weights of testes and accessory sex organs. Serum LH and testosterone were significantly reduced in all groups treated with analogues. There was a greater decrease in testicular weights and serum testosterone in nude mice which received SB-75 in a continuous fashion from minipumps than in animals injected twice a day. These results clearly demonstrate, contrary to the existing data, that the pituitary-gonadal axis of nude mice can be inhibited by LHRH agonists or antagonists if they are administered by continuous release systems. This study indicates that when the sustained-release formulations are used, nude mice can be valuable for studying the effects of analogues of LHRH on tumour biology
Journal of Endocrinology (1990) 126, 309–315
Title: Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists
Description:
ABSTRACT
Analogues of LHRH can be used for the treatment of sex hormone-dependent tumours.
The nude mouse is a valuable model for the investigation of transplanted human cancers, but there is a body of literature reporting that the function of the pituitary-gonadal axis in normal (immunocompetent) and nude (immunocompromized) mice, unlike that of other species, cannot be suppressed by the administration of LHRH agonists and antagonists.
To explore this view further, long-term experiments were carried out in nude male mice, in which sustained-release formulations of the agonist [d-Trp6]-LHRH and of two new potent antagonists were used which permitted a continuous release of the peptides into the circulation.
Nude male mice were treated for 28-30 days with 50 μg of antagonists [Ac-d-Nal(2)1,d-Phe(4Cl)2,d-Trp3,d-Cit6,d-Ala10]-LHRH (SB-30) or [Ac-d-Nal(2)1,d-Phe(4Cl)2,d-Pal(3)3,d-Cit6,d-Ala10]-LHRH (SB-75)/day delivered by osmotic minipumps.
Some mice were injected twice a day with 25 μg SB-75.
Other groups received microcapsule preparations of the agonist [d-Trp6]-LHRH, releasing 25 or 12·5 μg/day for 30 days.
At autopsy, in mice which received 50 μg SB-30 or SB-75/day by minipumps, there was a significant decrease in weights of testes, ventral prostate and seminal vesicles compared with controls.
[d-Trp6]-LHRH microcapsules at either dose also reduced weights of testes and accessory sex organs.
Serum LH and testosterone were significantly reduced in all groups treated with analogues.
There was a greater decrease in testicular weights and serum testosterone in nude mice which received SB-75 in a continuous fashion from minipumps than in animals injected twice a day.
These results clearly demonstrate, contrary to the existing data, that the pituitary-gonadal axis of nude mice can be inhibited by LHRH agonists or antagonists if they are administered by continuous release systems.
This study indicates that when the sustained-release formulations are used, nude mice can be valuable for studying the effects of analogues of LHRH on tumour biology
Journal of Endocrinology (1990) 126, 309–315.
Related Results
Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate
Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate
ABSTRACT
The LH and FSH release-stimulating (experiment 1) and -blocking (experiment 2) effects of LH-releasing hormone (LHRH) and of the LHRH analogue d-Ser(But)6-des-Gly1...
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
GH secretion was reevaluated after completion of GH treatment at a mean age of 19.2 ± 3.2 yr in 35 young adults with childhood-onset GH deficiency (GHD). The patients were subdivid...
COVID-19 induced hypercoagulability and its impact leading to pituitary apoplexy
COVID-19 induced hypercoagulability and its impact leading to pituitary apoplexy
I am writing this letter to address an increasingly high-risk but under-explored complication of pituitary apoplexy in patients who have contracted COVID-19. In light of recent res...
[RETRACTED] Rhino XL Male Enhancement v1
[RETRACTED] Rhino XL Male Enhancement v1
[RETRACTED]Rhino XL Reviews, NY USA: Studies show that testosterone levels in males decrease constantly with growing age. There are also many other problems that males face due ...
Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
Abstract
Understanding factors subserving pituitary cell proliferation enables understanding mechanisms underlying uniquely benign pituitary tumors. Pituitary tumor-...
Data from Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
Data from Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
<div>Abstract<p>Understanding factors subserving pituitary cell proliferation enables understanding mechanisms underlying uniquely benign pituitary tumors. Pituitary tu...
Data from Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
Data from Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
<div>Abstract<p>Understanding factors subserving pituitary cell proliferation enables understanding mechanisms underlying uniquely benign pituitary tumors. Pituitary tu...
GW24-e2259 Evaluation of atherosclerosis in low density lipoprotein receptor defect mice by ultrasound biomicroscopy
GW24-e2259 Evaluation of atherosclerosis in low density lipoprotein receptor defect mice by ultrasound biomicroscopy
Objectives
Low density lipoprotein receptor defect mice model by transgenetic technology was used to detect atherosclerosis by Ultrasound Biology (UBM). And evalu...

